Clinical Relevance of Matrix Metalloproteinase-13 Determined with a New Highly Specific and Sensitive ELISA in Ascitic Fluid of Advanced Ovarian Carcinoma Patients

B. Hantke; N. Harbeck; B. Schmalfeldt; I. Claes; O. Hiller; M.-O. Luther; A. Welk; W. Kuhn; M. Schmitt; H. Tschesche; B. Muehlenweg

doi:10.1515/BC.2003.137

Published by De Gruyter June 1, 2005

Clinical Relevance of Matrix Metalloproteinase-13 Determined with a New Highly Specific and Sensitive ELISA in Ascitic Fluid of Advanced Ovarian Carcinoma Patients

B. Hantke , N. Harbeck , B. Schmalfeldt , I. Claes , O. Hiller , M.-O. Luther , A. Welk , W. Kuhn , M. Schmitt , H. Tschesche and B. Muehlenweg

From the journal Biological Chemistry

https://doi.org/10.1515/BC.2003.137

Showing a limited preview of this publication:

Abstract

Matrix metalloproteinases (MMPs) are involved in many physiological and pathophysiological processes, including tumor cell invasion and metastasis. For one member of this family, MMP-13 (collagenase-3), a new, highly specific ELISA with a sensitivity of 0.5 ng MMP-13/ml was established. The protein levels of MMP-13 in ascitic fluids of 30 patients with advanced ovarian cancer FIGO stage III (n=19) and IV (n=11) were measured with this ELISA. Using a cutoff value of 0.5 ng MMP-13/mg total protein, two patient subpopulations with short (median 16 months) and long (median 36 months) overall survival were identified. Together with other prognostic markers, determination of MMP-13 in ascitic fluid may help to identify patients at risk for early death and help to individualize adjuvant therapy.

Published Online: 2005-06-01

Published in Print: 2003-08-20

Clinical Relevance of Matrix Metalloproteinase-13 Determined with a New Highly Specific and Sensitive ELISA in Ascitic Fluid of Advanced Ovarian Carcinoma Patients

Abstract

Journal and Issue

Articles in the same Issue